It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Particularly for older patients or those who are less able to travel to a clinician's office, monotherapy may better suit their therapeutic needs and lifestyles.Monotherapy is a common approach in CLL ...

Vepdegestrant has been recognized with fast track designation by the FDA and is being co-developed by Arvinas and Pfizer.

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations. Arvinas on ...

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer ...

Vepdegestrant, an investigational oral PROTAC ER degrader for ER+/HER2- breast cancer being jointly developed by Arvinas and Pfizer, is designed to harness the body’s natural protein disposal ...